Work

Axicabtagene Ciloleucel (axi‐cel; Kte‐c19) in Patients With Refractory Aggressive Non‐hodgkin Lymphomas (nhl): Primary Results of the Pivotal Trial Zuma‐1

Year: 2017

Type: conference-abstract

Source: Hematological Oncology

DOI: 10.1002/hon.2437_7

Authors: S.S. Neelapu, F.L. Locke, N.L. Bartlett, L.J. Lekakis, D. Miklos, C.A. Jacobson, I. Braunschweig, O. Oluwole, T. Siddiqi, Y. Lin, J. Timmerman, P. Reagan, L. Navale, Y. Jiang, J. Aycock, M. Elias, J. Wiezorek, W.Y. Go

Institutions: The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, Washington University in St. Louis, University of Miami Health System, Sylvester Comprehensive Cancer Center, Stanford Medicine, Stanford University, Dana-Farber Cancer Institute, Montefiore Medical Center, Montefiore Einstein Comprehensive Cancer Center, Vanderbilt University Medical Center, City Of Hope National Medical Center, City of Hope, Mayo Clinic, University of California, Los Angeles, University of Rochester Medicine, University of Rochester, Kite Pharma (United States)

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2622031359

Cites:

Cited by: 28

Related to: 10